Gastrointestinal Cancer

The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.

Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.

Developers anticipate launching a first-in-human phase 1 study assessing ziftomenib/imatinib for those with advanced GISTs in early 2025.

Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.

Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.

Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.

The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.

The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.

The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.

The FDA has set a Prescription Drug User Fee Act date of November 29, 2024, for zanidatamab in this biliary tract cancer population.

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.

Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.

Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.

The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.

The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

In-hospital mortality and complication rates were lower at accredited hospitals vs those not accredited for patients undergoing rectal cancer surgery.

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

The pilot trial is planning to enroll 20 patients who are deemed inoperable but do not have metastatic disease.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.